David Radin
Principal investigator.
Biotech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2015First federal award
$14.3MFederal grants as PI16 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
16 awards · $14.3M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Sep 1, 2019 | NIH | SBIR Phase I Lectin-mediated ERT Delivered to Cardiac Tissue in Fabry Disease | $293K | BIOSTRATEGIES LC |
| Aug 29, 2019 | NIH | SBIR Phase I Lectin-mediated ERT Delivered to Cardiac Tissue in Fabry Disease | $293K | BIOSTRATEGIES LC |
| Aug 31, 2018 | NIH | SBIR Phase II Enzyme replacement therapy for GM1 gangliosidosis lysosomal rare disease | $1.1M | BIOSTRATEGIES LC |
| Jul 19, 2018 | NIH | SBIR Phase II Improving MPS I ERT Efficacy through Lectin-Mediated Delivery | $1.1M | BIOSTRATEGIES LC |
| Jul 1, 2018 | NIH | SBIR Phase I MPS I Skeletal Disease Therapy with Novel Lectin-delivered Replacement Enzyme | $225K | BIOSTRATEGIES LC |
| Jun 12, 2018 | NIH | SBIR Phase I MPS I Skeletal Disease Therapy with Novel Lectin-delivered Replacement Enzyme | $225K | BIOSTRATEGIES LC |
| Sep 30, 2017 | NIH | SBIR Phase II Improving MPS I ERT Efficacy through Lectin-Mediated Delivery | $2.4M | BIOSTRATEGIES LC |
| Sep 25, 2017 | NIH | SBIR Phase II Improving MPS I ERT Efficacy through Lectin-Mediated Delivery | $1.2M | BIOSTRATEGIES LC |
| Sep 15, 2017 | NIH | SBIR Phase II Enzyme replacement therapy for GM1 gangliosidosis lysosomal rare disease | $2.4M | BIOSTRATEGIES LC |
| Sep 8, 2017 | NIH | SBIR Phase II Enzyme replacement therapy for GM1 gangliosidosis lysosomal rare disease | $1.4M | BIOSTRATEGIES LC |
| Aug 15, 2016 | NIH | SBIR Phase II Enzyme replacement therapy for Sanfilippo A lysosomal rare disease | $659K | BIOSTRATEGIES LC |
| Jul 6, 2016 | NIH | SBIR Phase I Enzyme Replacement Therapeutics for Rare Childhood Genetic Diseases: An ERT Delivery System that Mitigates Immune-sensitization | $225K | BIOSTRATEGIES LC |
| Jul 5, 2016 | NIH | SBIR Phase I Enzyme Replacement Therapeutics for Rare Childhood Genetic Diseases: An ERT Delivery System that Mitigates Immune-sensitization | $225K | BIOSTRATEGIES LC |
| Jul 15, 2015 | NIH | SBIR Phase II Enzyme replacement therapy for Sanfilippo A lysosomal rare disease | $1.5M | BIOSTRATEGIES LC |
| Jul 9, 2015 | NIH | SBIR Phase II Enzyme replacement therapy for Sanfilippo A lysosomal rare disease | $832K | BIOSTRATEGIES LC |
| Jul 2, 2015 | NIH | SBIR Phase I Improving MPS I ERT Efficacy through Lectin-Mediated Delivery | $186K | BIOSTRATEGIES LC |
Peer ranks
Federal funding#20
Awards as PI#37
Patents#273
Companies
- BIOSTRATEGIES LCLinked by awards · Biotech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.